Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06209736 is recruiting per multiple sources as of April 2026, with estimated primary completion Jan 2026. No public readout or results available. Phase 3 planning for C3G post-Phase 2 indicates ongoing, not yet read out.
Found Apr 6, 2026, 2:57 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial is recruiting with estimated primary completion in Jan 2026. No public efficacy readout or results posted for NCT06209736. Sponsor updates focus on PNH data (positive) and advancing this trial to Phase 3 without C3G/ICGN-specific efficacy statements. Evidence is absent/incomplete.
Found Apr 6, 2026, 2:08 PMReviewed Apr 6, 2026, 2:23 PM
ClinicalTrialsclinicaltrials.gov
Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Current status: Recruiting. Estimated primary completion: 2026-01-01. No results posted. Primary focus: safety, tolerability, PK/PD, and preliminary efficacy in ~20 patients.
Sponsorinvestor.omeros.comOct 24, 2024, 12:00 AM
FDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 Glomerulopathy
Phase 3 studies on the horizon in both PNH and C3G. Clinical studies ongoing in C3G; no efficacy data or readout mentioned for the Phase 2 trial.
Web Searchpmc.ncbi.nlm.nih.govJan 1, 2026, 12:00 AM
C3 Glomerulopathy Diagnosis, Current Treatments, and Emerging Therapies
Lists OMS906-C3G-001 (NCT06209736) as Phase 2, recruiting, open-label. No results or interpretation of efficacy provided.
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:52 PMReviewed Apr 4, 2026, 10:33 PM
NO_DECISIONDismissed98% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public Phase 2 readout was found for NCT06209736. The trial remains listed as recruiting on ClinicalTrials.gov, and Omeros said in its 2025 Q1 10-Q that the C3G Phase 2 study is still ongoing. Without a trial-specific efficacy/safety readout framed as positive or negative, outcome cannot be classified.
Found Apr 3, 2026, 5:20 PMReviewed Apr 3, 2026, 5:30 PM
NO_DECISIONDismissed95% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific Phase 2 readout for NCT06209736 was found. ClinicalTrials.gov still listed the study as recruiting/ongoing, Omeros’ SEC filing called the C3G study ongoing, and Omeros/Novo publicly cited positive Phase 2 data only for PNH—not this C3G/ICGN trial.
Found Apr 2, 2026, 5:14 PMReviewed Apr 3, 2026, 4:48 PM
NO_DECISIONDismissed96% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No public Phase 2 readout for this exact C3G/ICGN trial was found. Sponsor materials in late 2024 and March 2025 still describe the C3G study as open/ongoing, with dosing ongoing or the Phase 2 trial ongoing, not as having reported efficacy results. Therefore the outcome cannot be classified positive or negative.
Found Mar 31, 2026, 9:43 PMReviewed Apr 1, 2026, 6:34 AM
NO_DECISIONDismissed98% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
The cited evidence indicates this exact Phase 2 trial has remained ongoing rather than publicly read out. ClinicalTrials.gov lists NCT06209736 as a Phase 2 proof-of-concept study with estimated primary completion in January 2026, and Omeros stated in 2025 SEC filings that its C3G Phase 2 study was still ongoing. Because I found no cited source with a trial-specific positive or negative interpretation of results for NCT06209736, the correct classification is no_decision.
Found Mar 30, 2026, 4:35 AMReviewed Mar 30, 2026, 7:04 AM
ClinicalTrialsclinicaltrials.gov
Study Details | NCT06209736 | Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN | ClinicalTrials.gov
ClinicalTrials.gov identifies NCT06209736 as "A Phase 2 Proof of Concept Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of OMS906 in Patients With C3 Glomerulopathy (C3G) and Idiopathic Immune Complex-Mediated Glomerulonephritis (ICGN)." The registry entry shows estimated primary completion in January 2026.
Sponsorsec.govMay 9, 2025, 12:00 AM
Omeros Quarterly Report on Form 10-Q for period ended March 31, 2025
Omeros states: "We also have a small, ongoing Phase 2 study evaluating zaltenibart in complement 3 glomerulopathy ("C3G"), a rare and debilitating renal disease driven by complement dysregulation."
Sponsorsec.govMar 31, 2025, 12:00 AM
Omeros Annual Report on Form 10-K for year ended December 31, 2024
In the pipeline table, Omeros lists zaltenibart for "Complement 3 glomerulopathy (C3G) and other alternative pathway disorders" as "Phase 2 program ongoing" with the next step "Complete Phase 2 study and initiate Phase 3 clinical trial."